Literature DB >> 21394747

A method to estimate treatment efficacy among latent subgroups of a randomized clinical trial.

Lily L Altstein1, Gang Li, Robert M Elashoff.   

Abstract

Subgroup analysis arises in clinical trials research when we wish to estimate a treatment effect on a specific subgroup of the population distinguished by baseline characteristics. Many trial designs induce latent subgroups such that subgroup membership is observable in one arm of the trial and unidentified in the other. This occurs, for example, in oncology trials when a biopsy or dissection is performed only on subjects randomized to active treatment. We discuss a general framework to estimate a biological treatment effect on the latent subgroup of interest when the survival outcome is right-censored and can be appropriately modelled as a parametric function of covariate effects. Our framework builds on the application of instrumental variables methods to all-or-none treatment noncompliance. We derive a computational method to estimate model parameters via the EM algorithm and provide guidance on its implementation in standard software packages. The research is illustrated through an analysis of a seminal melanoma trial that proposed a new standard of care for the disease and involved a biopsy that is available only on patients in the treatment arm.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21394747      PMCID: PMC3161831          DOI: 10.1002/sim.4131

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

1.  Correcting for non-compliance in randomized trials: an application to the ATBC Study.

Authors:  P A Korhonen; N M Laird; J Palmgren
Journal:  Stat Med       Date:  1999-11-15       Impact factor: 2.373

2.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

3.  A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.

Authors:  T Loeys; E Goetghebeur
Journal:  Biometrics       Date:  2003-03       Impact factor: 2.571

4.  Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods.

Authors:  Graham Dunn; Mohammad Maracy; Barbara Tomenson
Journal:  Stat Methods Med Res       Date:  2005-08       Impact factor: 3.021

5.  Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.

Authors:  A James O'Malley; Sharon-Lise T Normand
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

6.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 7.  A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial.

Authors:  S D Mark; J M Robins
Journal:  Control Clin Trials       Date:  1993-04

8.  On estimating efficacy from clinical trials.

Authors:  A Sommer; S L Zeger
Journal:  Stat Med       Date:  1991-01       Impact factor: 2.373

9.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

10.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

  10 in total
  10 in total

1.  SLNB in melanoma-DFS a true and cost-effective benefit?

Authors:  Alexander C J van Akkooi; Alexander M M Eggermont
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

2.  MSLT-I-response of clinical trial investigators.

Authors:  Mark B Faries; Alistair J Cochran; John F Thompson
Journal:  Nat Rev Clin Oncol       Date:  2014-10-14       Impact factor: 66.675

3.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

4.  Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'.

Authors:  M B Faries; A J Cochran; R M Elashoff; J F Thompson
Journal:  Br J Dermatol       Date:  2015-03       Impact factor: 9.302

5.  Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

Authors:  L Altstein; G Li
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

6.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

7.  Sentinel lymph node biopsy for melanoma: a plea to let the data be heard.

Authors:  John F Thompson; Mark B Faries; Alistair J Cochran
Journal:  Ann Surg Oncol       Date:  2014-08-08       Impact factor: 5.344

8.  A semiparametric linear transformation model to estimate causal effects for survival data.

Authors:  Huazhen Lin; Yi Li; Liang Jiang; Gang Li
Journal:  Can J Stat       Date:  2013-11-14       Impact factor: 0.875

9.  Designing and analyzing clinical trials for personalized medicine via Bayesian models.

Authors:  Chuanwu Zhang; Matthew S Mayo; Jo A Wick; Byron J Gajewski
Journal:  Pharm Stat       Date:  2021-01-19       Impact factor: 1.894

Review 10.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.